Jill Feldman, Co-Founder of EGFR Resisters, shared a post on X:
“Dr Shokat talk at opening plenary at AACR25 on how progress in studying KRAS, historically known as ‘undruggable’, led to developing drugs to target it. Never say never… The impossible can be possible.”
